Another public discussion of Sarepta Therapeutics, Inc.’s gene therapy for Duchenne muscular dystrophy Elevidys may be on the horizon after the product missed the primary endpoint in its confirmatory study.
The company tried to spin the miss as a success, arguing that secondary endpoint data shows that Elevidys (delandistrogene moxeparvovec-rokl)...







